drugset / Trial / NCT01353040
Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
Phase 1
Completed
30 enrolled
Sarepta Therapeutics, Inc.
United States Department of Defense · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.
Timeline
- Start
- 2011-05
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVI-6003 | Antisense oligonucleotide | — | Intravenous |